- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07698041
RUTISS-Diary and RUTISS-65 Study
Developing and Validating Two New Patient-Reported Outcome Measures of Recurrent Urinary Tract Infection Symptoms: A Symptoms Diary and Adapted Measure for Older Adults
Studie Overzicht
Toestand
Gedetailleerde beschrijving
400 million people globally each year are affected by Urinary Tract Infections (UTIs) (Yang et al., 2022), with annual recurrence ranging from 24-50% (Foxman, 2014). Recurrent UTI (rUTI), defined as at least two UTIs in six months or at least three in one year (Bonkat et al., 2020), negatively affects quality of life (Wagenlehner et al., 2018) and repeat treatment risks antimicrobial resistance (Ormeño et al., 2022). Standard urine culture may present results discrepant with symptoms (Harding et al., 2022), hence the urgent need for quantifiable rUTI Patient Reported Outcome Measures (PROMs). Measures exist for acute infection (e.g. cystitis (Alidjanov et al., 2018) but not rUTI. We recently developed, published and commercially licensed two rUTI PROMs (the Recurrent Urinary Tract Infection Symptom Scale; RUTISS (Newlands et al., 2023) and the Recurrent Urinary Tract Infection Impact Questionnaire; RUTIIQ; Newlands et al., 2023b). However, neither has been adapted for daily symptom tracking or tailored to the needs of older adults. As a result, there is no rapid assessment tool that individuals living with rUTI (or their healthcare professionals) to analyse how rUTI symptoms change daily or to suitably assess adults over 65 years. This study aims to develop, validate and pilot two PROMs: 1) an adaptation of the RUTISS in daily diary format (RUTISS-Diary); and 2) an adapted RUTISS measure adapted for observational reporting of rUTI symptoms in older adults (RUTISS-65).
To inform the items of the RUTISS-Diary and RUTISS-65, extensive multiphase, mixed-methods preparatory work has been completed to ensure the items are informed from both patient and clinician perspectives. Phase 1 comprised of one-to-one interviews conducted with clinical experts working with older adults experiencing recurrent urinary tract infections (inclusive of urology, microbiology and geriatrics, N = 10, completed, UoR ethics ref: 2025-039-KF). This was accompanied by a literature review specific to older adult experiences of rUTI and patient interviews with outpatient members of Live UTI Free (N = 20, completed, UoR ethics ref: 2024-071-KF). Phase 2 consisted of two-rounds of HCP expert panel Delphi-surveys (N = 11) and cognitive interviews with expert patients (N = 25) for refinement of the measures (completed, UoR ethics ref: 2025-039-KF). These first phases are complete, informing the items of the RUTISS-Diary and RUTISS-65. The present study therefore aims to test and validate these measures to ensure they are reliable and are able to detect meaningful change.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Katherine A Finlay, PhD, CPsychol
- Telefoonnummer: 0118 378 8523
- E-mail: katherine.finlay@reading.ac.uk
Studie Contact Back-up
- Naam: Lydia V Tidmarsh, PhD
- Telefoonnummer: 0118 378 8523
- E-mail: l.v.tidmarsh@reading.ac.uk
Studie Locaties
-
-
-
Reading, Verenigd Koninkrijk
- Royal Berkshire NHS Foundation Trust
-
Reading, Verenigd Koninkrijk, RG6 6ET
- University of Reading
-
Contact:
- Katherine A Finlay, PhD, CPsychol
- Telefoonnummer: 0118 378 8523
- E-mail: katherine.finlay@reading.ac.uk
-
Contact:
- Lydia V Tidmarsh, PhD
- Telefoonnummer: 0118 378 8523
- E-mail: l.v.tidmarsh@reading.ac.uk
-
Hoofdonderzoeker:
- Bob Yang, FRCS (UROL), MBBS, BSC (HONS)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion for RUTISS-Diary:
- Participants must be 18 years and older
- All participants must have native/bilingual or advanced fluency in English.
- Access to a computer/mobile device for survey completion.
- Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).
Inclusion for RUTISS- 65:
- Participants must be 65 years and older
- Access to a computer/mobile device for survey completion, paper copy available upon request.
- All participants must have native/bilingual or advanced fluency in English.
- Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).
Exclusion criteria (for RUTISS-Diary and RUTISS-65)
- Participants must not report a current diagnosis of interstitial cystitis (measured in demographics questionnaire).
- Symptoms of cognitive confusion or dementia.
- No active malignancy e.g. bladder or prostate cancer
- Participants must not report beginner or intermediate level fluency in English. Future work will be done to translate the PROMs into alternative languages.
- In addition to the interstitial cystitis exclusion question, participants will also be asked in the demographic questionnaire if they are pregnant or have an indwelling catheter or use intermittent self-catheterisation. Participants who report "yes" to either of these will be excluded from participation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
RUTISS-Diary (Cohort A)
All rUTI patients of any age
|
RUTISS-Diary
|
|
RUTISS-65 (Cohort B)
rUTI patients aged 65 years and over
|
RUTISS-Diary
RUTISS-65
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Test-retest reliability
Tijdsspanne: RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Primary outcome measures will include the test-retest reliability and construct validity of the instrument.
Test-retest reliability will be assessed by calculating intraclass correlation coefficients (ICCs) for each subscale at each time point.
|
RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
|
Construct validity
Tijdsspanne: RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Construct validity will be examined using correlation analyses between the subscales of the study measures and relevant comparative measures.
|
RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sensitivity to change
Tijdsspanne: RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Secondary outcome measures will assess the responsiveness (sensitivity to change) of the RUTISSdiary and RUTISS-65 using both anchor-based and distribution-based approaches, in line with COSMIN recommendations for continuous outcome measures (COSMIN, 2019).
|
RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Katherine A Finlay, PhD, CPsychol, University of Reading
- Hoofdonderzoeker: Bob Yang, FRCS (UROL), MBBS, BSC (HONS), Royal Berkshire NHS Foundation Trust
Publicaties en nuttige links
Algemene publicaties
- Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1-13. doi: 10.1016/j.idc.2013.09.003. Epub 2013 Dec 8.
- Newlands AF, Roberts L, Maxwell K, Kramer M, Price JL, Finlay KA. Development and psychometric validation of a patient-reported outcome measure of recurrent urinary tract infection impact: the Recurrent UTI Impact Questionnaire. Qual Life Res. 2023 Jun;32(6):1745-1758. doi: 10.1007/s11136-023-03348-7. Epub 2023 Feb 6.
- Newlands AF, Kramer M, Roberts L, Maxwell K, Price JL, Finlay KA. Confirmatory structural validation and refinement of the Recurrent Urinary Tract Infection Symptom Scale. BJUI Compass. 2023 Oct 4;5(2):240-252. doi: 10.1002/bco2.297. eCollection 2024 Mar.
- Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FME. Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis. Antibiotics (Basel). 2018 Jan 15;7(1):6. doi: 10.3390/antibiotics7010006.
- Harding C, Mossop H, Homer T, Chadwick T, King W, Carnell S, Lecouturier J, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022 Mar 9;376:e068229. doi: 10.1136/bmj-2021-0068229.
- Ormeno MA, Ormeno MJ, Quispe AM, Arias-Linares MA, Linares E, Loza F, Ruiz J, Pons MJ. Recurrence of Urinary Tract Infections due to Escherichia coli and Its Association with Antimicrobial Resistance. Microb Drug Resist. 2022 Feb;28(2):185-190. doi: 10.1089/mdr.2021.0052. Epub 2021 Aug 27.
- Wagenlehner F, Wullt B, Ballarini S, Zingg D, Naber KG. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):107-117. doi: 10.1080/14737167.2017.1359543. Epub 2017 Jul 31.
- Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front Public Health. 2022 Jul 27;10:888205. doi: 10.3389/fpubh.2022.888205. eCollection 2022.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Pijn
- Neurologische manifestaties
- Mannelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Infecties
- Pathologische aandoeningen, tekenen en symptomen
- Gedrag
- Tekenen en symptomen
- Therapietrouw en therapietrouw
- Gezondheidsgedrag
- Chronische pijn
- Urologische ziekten
- Urineweginfecties
- Tevredenheid van de patiënt
Andere studie-ID-nummers
- 2026-028-KF
- IRAS ID: 366353 (Ander subsidie-/financieringsnummer: HRA and HCRW)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .